- Home
- ARQQ vs MREO Comparison
ARQQ vs MREO Comparison
Compare ARQQ & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQQ | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARQQ | MREO |
|---|---|---|
| Price | $23.63 | $0.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $60.00 | $3.90 |
| AVG Volume (30 Days) | 311.8K | ★ 39.0M |
| Earning Date | 12-09-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,000.00 | $500,000.00 |
| Revenue This Year | $1,054.72 | N/A |
| Revenue Next Year | $30.00 | $6,363.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.00 | $0.20 |
| 52 Week High | $62.00 | $3.26 |
Technical Indicators
Market Signals| Indicator | ARQQ | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 31.34 |
| Support Level | $23.22 | $0.48 |
| Resistance Level | $28.15 | $0.78 |
| Average True Range (ATR) | 1.74 | 0.09 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 14.34 | 26.56 |
Price Performance
Historical ComparisonAbout ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).